S&P Futures
4,162.00 +31.50 (+0.76%) Dow Futures
34,201.00 +206.00 (+0.61%) Nasdaq Futures
12,702.75 +157.50 (+1.26%) Russell 2000 Futures
1,963.00 +13.10 (+0.67%) Crude Oil
77.88 -0.59 (-0.75%) Gold
1,898.70 +8.00 (+0.42%)
Pre-Market:
Chart Events
Performance Outlook
| Previous Close | 9.74 |
| Open | 9.68 |
| Bid | 7.10 x 800 |
| Ask | 9.73 x 900 |
| Day's Range | 9.27 - 9.73 |
| 52 Week Range | 6.84 - 17.68 |
| Volume | |
| Avg. Volume | 584,554 |
| Market Cap | 774.086M |
| Beta (5Y Monthly) | 1.03 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.45 |
| Earnings Date | Feb 22, 2023 - Feb 27, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 22.67 |
- Simply Wall St.
We're Not Very Worried About Alector's (NASDAQ:ALEC) Cash Burn Rate
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
- GlobeNewswire
Alector Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., Dec. 08, 2022 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology and innate immuno-oncology, today announced that on December 6, 2022, the compensation committee of Alector’s board of directors granted 8 (eight) new employees options to purchase an aggregate of 91,851 shares of the company’s common stock and restricted stock units (RSUs) for an aggregate of 40,961 shares of the company’s common stock.
- GlobeNewswire
Alector Presents Results from First-in-Human Phase 1 Study of AL101 for the Treatment of Neurodegenerative Diseases
AL101 is being developed to elevate progranulin (PGRN) levels with dosing regimens to be optimized for larger indications such as Alzheimer’s disease Study results in healthy volunteers demonstrated that AL101 increased the level of PGRN, a key regulator of immune activity and lysosomal function in the brain SOUTH SAN FRANCISCO, Calif., Nov. 29, 2022 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology and innate immuno-oncology, re
